Researchers develop NPHP5 gene therapy for rare ciliopathy
The researchers found that augmenting NPHP5 gene rescues cilia defects in light-sensing cells derived from ciliopathy patients.
List view / Grid view
The researchers found that augmenting NPHP5 gene rescues cilia defects in light-sensing cells derived from ciliopathy patients.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
Genome editing technologies could accelerate the translation of genetic advances into new therapeutics. Here, Dr Pushpanathan Muthuirulan, Research Associate at Harvard University, explores the potential of CRISPR to treat and cure genetic conditions.
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
Included in this ebook are pieces on how an assay for the detection of sepsis was developed and a new high-throughput assay that could reveal new drugs to fight COVID-19.
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
In this episode, experts discuss how they use ELISA assays in their research as well as the specific benefits of this kind of immunoassay.
Molecular Devices has announced a collaboration with HeartBeat.bio to develop cardiac organoids for use in drug discovery.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
The researchers found that ketone body deficiency in neonatal mice resulted in smaller ovarian follicle reservoir because of the increased apoptosis of primordial follicles.
References for ‘Advancing vaccines with extracellular vesicles’, in Drug Target Review Issue 3 2022.
A powerful tool to study complex phenotypes and cellular interactions. Map spatial interactions twice as fast with this second-generation system.
A recent genomic surveillance study has demonstrated the value of genomics to inform vaccine design and highlight the challenge posted by shapeshifting bacteria.